Loading...
Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials
BACKGROUND: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. RESULTS: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.44 − 0.63; p < 0.00001) and 0.87 (95% CI, 0....
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4914353/ https://ncbi.nlm.nih.gov/pubmed/26657509 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6507 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|